CohBar, Inc. is an innovative biotechnology company focused on the research and development of Mitochondria Based Therapeutics (MBTs), an emerging class of proprietary drugs for the treatment of age-related diseases. MBTs originate from the discovery by our founders of a novel group of previously unexplored peptides encoded within the mitochondrial genome.

Our mission is to increase healthy lifespan by harnessing the power of these mitochondrial peptides to treat the metabolic dysfunction underlying major age related diseases. Our MBTs have the potential to treat a wide range of diseases including NASH, obesity, cancer, diabetes, and cardiovascular and CNS diseases.